[{"Assets_0_Q3_USD":208251000.0,"CommonStockSharesOutstanding_0_Q3_shares":630952736.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-99979000.0,"NetIncomeLoss_1_Q3_USD":-39302000.0,"NetIncomeLoss_3_Q3_USD":-107801000.0,"EarningsPerShareBasic_1_Q3_USD":-0.06,"EarningsPerShareBasic_3_Q3_USD":-0.17,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":630866800.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":629403293.0,"Ticker":"ADAP","CIK":"1621227","name":"ADAPTIMMUNE THERAPEUTICS PLC","OfficialName":"Adaptimmune Therapeutics plc American Depositary Shares","form":"10-Q","period":"20190930","fy":"2019.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"301181409.0","Country":"United Kingdom","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20191106"}]